These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2958853)

  • 1. Treatment of advanced carcinoma of the prostate by LHRH-agonists.
    Claes HI; Vandenbussche L; Vereecken RL
    Prog Clin Biol Res; 1987; 243A():229-37. PubMed ID: 2958853
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of advanced cancer of the prostate using LHRH analogs. How can a possible initial flare-up be prevented?].
    Bouffioux C; Denis L; Mahler C; de Leval J
    Acta Urol Belg; 1986; 54(3):304-8. PubMed ID: 2946208
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
    Moffat LE
    Eur Urol; 1990; 18 Suppl 3():26-7. PubMed ID: 2151272
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of advanced prostatic cancer with LHRH-analogues. Prevention of "flare-up" phenomenon.
    Bouffioux C; Denis L; Mahler C; de Leval J
    Prog Clin Biol Res; 1987; 243A():255-60. PubMed ID: 2958857
    [No Abstract]   [Full Text] [Related]  

  • 5. LHRH-analogues therapy for metastatic prostate cancer.
    Debruyne FM; Fernandez del Moral P; Geboers AD
    Prog Clin Biol Res; 1988; 260():27-39. PubMed ID: 2966406
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate.
    Paisey RB; Kadow C; Bolton C; Hartog M; Gingell JC
    J R Soc Med; 1986 Apr; 79(4):210-1. PubMed ID: 2939240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
    Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A 79-year-old man with metastatic prostate cancer, treated with Zoladex, flutamide, calcitonin and Ostac, suffers from frequent troublesome sweating with palpitation and angina pectoris, especially at night. Is there a therapy?].
    Schmeller N
    Internist (Berl); 1992 Apr; 33(4):284. PubMed ID: 1535344
    [No Abstract]   [Full Text] [Related]  

  • 9. Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist.
    Kreis W; Budman DR; Delli Bovi P; Vinciguerra V
    Onkologie; 1988 Dec; 11(6):292-3. PubMed ID: 2977219
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
    Allen JM; Williams G; O'Shea JP; Smith C; Yeo T; Kerle D; Bloom SR
    Urol Res; 1984; 12(5):249-51. PubMed ID: 6240150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
    Senn E; Müller J; Alioth H
    Schweiz Rundsch Med Prax; 1985 Nov; 74(48):1340-4. PubMed ID: 3003863
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
    Nicholson RI; Walker KJ
    Chemioterapia; 1985 Jun; 4(3):249-51. PubMed ID: 3161643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results obtained in the treatment of prostate cancer patients with Zoladex.
    Williams G; Kerle DJ; Roe SM; Yeo T; Bloom SR
    Prog Clin Biol Res; 1985; 185A():287-95. PubMed ID: 3162175
    [No Abstract]   [Full Text] [Related]  

  • 14. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
    Di Silverio F; Serio M; D'Eramo G; Sciarra F
    Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
    Di Silverio F; Sciarra F; D'Eramo G
    Eur Urol; 1990; 18(1):10-5. PubMed ID: 2144819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H; Senge T
    J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.